Data / Drug companies / Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor drugs: 6 drugs from 9 companies in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 21 products in this class from 9 companies, covering 6 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on October 14, 2026.
The request: Get every company that lists a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 9Companies
- 21Products
- 6Drugs by generic name
Drugs in the Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Raltegravir | 10 | 6 |
| Dolutegravir sodium | 5 | 2 |
| Abacavir sulfate, dolutegravir sodium, lamivudine | 1 | 1 |
| Cabotegravir sodium | 1 | 1 |
| Dolutegravir sodium and lamivudine | 1 | 1 |
| Dolutegravir sodium and rilpivirine hydrochloride | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| ViiV Healthcare Company | 8 | tablet, film coated; tablet, for suspension | New drug applications (NDA) | January 21, 2021 |
| Merck Sharp & Dohme LLC | 5 | tablet, film coated; tablet, chewable | New drug applications (NDA) | May 26, 2017 |
| Gilead Sciences, Inc. | 2 | tablet; tablet, film coated | New drug applications (NDA) | November 5, 2015 |
| A-S Medication Solutions | 1 | tablet, film coated | New drug applications (NDA) | October 12, 2007 |
| Camber Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | December 19, 2024 |
| Lupin Pharmaceuticals, Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | October 14, 2026 |
| NuCare Pharmaceuticals,Inc. | 1 | tablet, film coated | New drug applications (NDA) | October 12, 2007 |
| Proficient Rx LP | 1 | tablet, film coated | New drug applications (NDA) | October 12, 2007 |
| St. Mary's Medical Park Pharmacy | 1 | tablet, film coated | New drug applications (NDA) | August 13, 2013 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 16 | 76.2% |
| Tablet, chewable | 2 | 9.5% |
| Tablet, for suspension | 1 | 4.8% |
| Tablet | 1 | 4.8% |
| Granule, for suspension | 1 | 4.8% |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.